We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
BioMarin Withdraws Kyndrisa Marketing Application in EU
Read MoreHide Full Article
BioMarin Pharmaceutical Inc. (BMRN - Free Report) announced that it has withdrawn a Marketing Authorisation Application (MAA) for Kyndrisa (drisapersen) from the EU, following discussions with the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP), which hinted at the issuance of a negative opinion.
The company was seeking an approval for Kyndrisa for the treatment of Duchenne muscular dystrophy (DMD), amenable to exon 51 skipping.
BioMarin said that it will also discontinue the development of the three follow-on products of Kyndrisa – BMN 044, BMN 045, and BMN 053 – which are currently being evaluated in phase II studies for specific forms of DMD. Nevertheless, the company intends to work on the development of a transition plan for the patients who are currently being treated with these candidates.
Meanwhile, the company stated that it will continue to develop next generation oligonucleotides for the treatment of DMD.
Despite the fact that a MAA was withdrawn from the EU, BioMarin continues to expect to achieve break-even or better results in 2017.
We remind investors that in Jan 2016, the FDA issued a Complete Response Letter (CRL) related to the company’s New Drug Application (NDA) for Kyndrisa for the same indication. The agency rejected the application, citing that Kyndrisa had failed to meet the standard of substantial evidence of effectiveness in treating DMD.
DMD, a devastating and debilitating disease, is estimated to affect nearly 1 in every 3,500–5,000 boys born across the world, indicating significant unmet need for treatments in this space.
We note that Sarepta Therapeutics, Inc. (SRPT - Free Report) is also looking to get its DMD drug approved. Last week, the company announced that the FDA has extended the Prescription Drug User Fee Act (PDUFA) date for its DMD candidate, eteplirsen, which was scheduled for May 26. The agency reported that it intends to come up with a decision as early as possible.
Currently, BioMarin carries a Zacks Rank #3 (Hold). Bristol-Myers Squibb Company (BMY - Free Report) and ANI Pharmaceuticals, Inc. (ANIP - Free Report) are a couple of better-ranked stocks in the health care sector, both sporting a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.Click to get this free report >>
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
BioMarin Withdraws Kyndrisa Marketing Application in EU
BioMarin Pharmaceutical Inc. (BMRN - Free Report) announced that it has withdrawn a Marketing Authorisation Application (MAA) for Kyndrisa (drisapersen) from the EU, following discussions with the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP), which hinted at the issuance of a negative opinion.
The company was seeking an approval for Kyndrisa for the treatment of Duchenne muscular dystrophy (DMD), amenable to exon 51 skipping.
BioMarin said that it will also discontinue the development of the three follow-on products of Kyndrisa – BMN 044, BMN 045, and BMN 053 – which are currently being evaluated in phase II studies for specific forms of DMD. Nevertheless, the company intends to work on the development of a transition plan for the patients who are currently being treated with these candidates.
Meanwhile, the company stated that it will continue to develop next generation oligonucleotides for the treatment of DMD.
Despite the fact that a MAA was withdrawn from the EU, BioMarin continues to expect to achieve break-even or better results in 2017.
We remind investors that in Jan 2016, the FDA issued a Complete Response Letter (CRL) related to the company’s New Drug Application (NDA) for Kyndrisa for the same indication. The agency rejected the application, citing that Kyndrisa had failed to meet the standard of substantial evidence of effectiveness in treating DMD.
DMD, a devastating and debilitating disease, is estimated to affect nearly 1 in every 3,500–5,000 boys born across the world, indicating significant unmet need for treatments in this space.
We note that Sarepta Therapeutics, Inc. (SRPT - Free Report) is also looking to get its DMD drug approved. Last week, the company announced that the FDA has extended the Prescription Drug User Fee Act (PDUFA) date for its DMD candidate, eteplirsen, which was scheduled for May 26. The agency reported that it intends to come up with a decision as early as possible.
Currently, BioMarin carries a Zacks Rank #3 (Hold). Bristol-Myers Squibb Company (BMY - Free Report) and ANI Pharmaceuticals, Inc. (ANIP - Free Report) are a couple of better-ranked stocks in the health care sector, both sporting a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.Click to get this free report >>